Investor Presentation H1 2023

12 Investor presentation First six months of 2023 Semaglutide 2.4 mg showed 20% MACE reduction in the SELECT trial for people with overweight or obesity and established CVD Novo NordiskⓇ SELECT trial with 17,604 people with BMI>27 and established CVD Semaglutide 2.4 mg R 1:1 Placebo Primary endpoint • Event driven 5 weeks follow-up Time from randomisation to first occurrence of 3-point MACE¹ Secondary confirmatory endpoints Time from randomisation to first occurrence of: • CV death • HF composite endpoint All-cause death Objective • Demonstrate that semaglutide s.c. 2.4 mg OW lowers the incidence MACE vs. placebo when both added to standard of care in subjects with established CV disease and overweight or obesity. Headline results . Semaglutide 2.4 mg demonstrated an 20% reduction in MACE Safety • In the trial, once-weekly subcutaneous semaglutide 2.4 mg appeared to have a safe and well-tolerated profile, as seen with previous trials investigating semaglutide 2.4 mg Next steps • Novo Nordisk expects to file for regulatory approvals of the label indication expansion for semaglutide 2.4 mg in the US and the EU during 2023 • Full data set to be presented at scientific congress in H2 2023 1MACE includes non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. MACE: Major adverse cardiovascular events; HF: Heart failure; CV: Cardiovascular; CVD: Cardiovascular Disease; OW: Once-weekly; s.c.: Subcutaneous; BMI: Body mass index

View entire presentation